Molecular Dynamics of the Full-length P53 Monomer

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2013 Aug 27

PMID 23974096

Citations 23

Authors

Giovanni Chillemi

Pavel Davidovich

Marco DAbramo

Tazhir Mametnabiev

Alexander Vasilievich Garabadzhiu

Alessandro Desideri

Gerry Melino

Affiliations

Soon will be listed here.

Abstract

The p53 protein is frequently mutated in a very large proportion of human tumors, where it seems to acquire gain-of-function activity that facilitates tumor onset and progression. A possible mechanism is the ability of mutant p53 proteins to physically interact with other proteins, including members of the same family, namely p63 and p73, inactivating their function. Assuming that this interaction might occurs at the level of the monomer, to investigate the molecular basis for this interaction, here, we sample the structural flexibility of the wild-type p53 monomeric protein. The results show a strong stability up to 850 ns in the DNA binding domain, with major flexibility in the N-terminal transactivations domains (TAD1 and TAD2) as well as in the C-terminal region (tetramerization domain). Several stable hydrogen bonds have been detected between N-terminal or C-terminal and DNA binding domain, and also between N-terminal and C-terminal. Essential dynamics analysis highlights strongly correlated movements involving TAD1 and the proline-rich region in the N-terminal domain, the tetramerization region in the C-terminal domain; Lys120 in the DNA binding region. The herein presented model is a starting point for further investigation of the whole protein tetramer as well as of its mutants.

Citing Articles

p53: The Multifaceted Roles of Covalent Modifications in Cancer.

Grigoreva T, Romanova A, Tribulovich V, Pestov N, Oganov R, Kovaleva D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770524 PMC: 11677429. DOI: 10.3390/ph17121682.

Molecular dynamics-based computational investigations on the influence of tumor suppressor p53 binding protein against other proteins/peptides.

Abdalla M, Abdelkhalig S, Edet U, Zothantluanga J, Umoh E, Moglad E Sci Rep. 2024; 14(1):29871.

PMID: 39622863 PMC: 11612205. DOI: 10.1038/s41598-024-81499-4.

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA.

Islam S, Hasan M, Alam J, Dey A, Molineaux D Proteins. 2024; 93(2):498-514.

PMID: 39264222 PMC: 11695177. DOI: 10.1002/prot.26747.

Elucidating structural variability in p53 conformers using combinatorial refinement strategies and molecular dynamics.

Parves M, Solares M, Dearnaley W, Kelly D Cancer Biol Ther. 2023; 25(1):2290732.

PMID: 38073067 PMC: 10732606. DOI: 10.1080/15384047.2023.2290732.

Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases.

Naskar S, Gour N Life (Basel). 2023; 13(7).

PMID: 37511898 PMC: 10381831. DOI: 10.3390/life13071523.

References

Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O . Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol. 1986; 6(9):3232-9. PMC: 367060. DOI: 10.1128/mcb.6.9.3232-3239.1986. View

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F . MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2011; 19(6):1038-48. PMC: 3354056. DOI: 10.1038/cdd.2011.190. View

Conforti F, Sayan A, Sreekumar R, Sayan B . Regulation of p73 activity by post-translational modifications. Cell Death Dis. 2012; 3:e285. PMC: 3317350. DOI: 10.1038/cddis.2012.27. View

Wang G, Fersht A . First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci U S A. 2012; 109(34):13590-5. PMC: 3427100. DOI: 10.1073/pnas.1211557109. View

Gordo S, Martos V, Santos E, Menendez M, Bo C, Giralt E . Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand. Proc Natl Acad Sci U S A. 2008; 105(43):16426-31. PMC: 2575436. DOI: 10.1073/pnas.0805658105. View

Feldser D, Kostova K, Winslow M, Taylor S, Cashman C, Whittaker C . Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010; 468(7323):572-5. PMC: 3003305. DOI: 10.1038/nature09535. View

Rouaud P, Fiancette R, Vincent-Fabert C, Magnone V, Cogne M, Dubus P . Mantle cell lymphoma-like lymphomas in c-myc-3'RR/p53+/- mice and c-myc-3'RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin. Oncotarget. 2012; 3(5):586-93. PMC: 3388189. DOI: 10.18632/oncotarget.474. View

Seillier M, Peuget S, Gayet O, Gauthier C, NGuessan P, Monte M . TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ. 2012; 19(9):1525-35. PMC: 3422476. DOI: 10.1038/cdd.2012.30. View

Vaseva A, Yallowitz A, Marchenko N, Xu S, Moll U . Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis. 2011; 2:e156. PMC: 3122118. DOI: 10.1038/cddis.2011.39. View

10.

Maddocks O, Berkers C, Mason S, Zheng L, Blyth K, Gottlieb E . Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2012; 493(7433):542-6. PMC: 6485472. DOI: 10.1038/nature11743. View

11.

Macchiarulo A, Giacche N, Carotti A, Baroni M, Cruciani G, Pellicciari R . Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model. 2008; 48(10):1999-2009. DOI: 10.1021/ci800146m. View

12.

Okorokov A, Sherman M, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G . The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J. 2006; 25(21):5191-200. PMC: 1630404. DOI: 10.1038/sj.emboj.7601382. View

13.

Nagaich A, Zhurkin V, Durell S, Jernigan R, Appella E, Harrington R . p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. Proc Natl Acad Sci U S A. 1999; 96(5):1875-80. PMC: 26704. DOI: 10.1073/pnas.96.5.1875. View

14.

Jiang P, Du W, Mancuso A, Wellen K, Yang X . Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature. 2013; 493(7434):689-93. PMC: 3561500. DOI: 10.1038/nature11776. View

15.

Agostini M, Tucci P, Killick R, Candi E, Sayan B, Rivetti di Val Cervo P . Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A. 2011; 108(52):21093-8. PMC: 3248477. DOI: 10.1073/pnas.1112061109. View

16.

Junttila M, Karnezis A, Garcia D, Madriles F, Kortlever R, Rostker F . Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010; 468(7323):567-71. PMC: 3011233. DOI: 10.1038/nature09526. View

17.

Bochkareva E, Kaustov L, Ayed A, Yi G, Lu Y, Pineda-Lucena A . Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A. 2005; 102(43):15412-7. PMC: 1266094. DOI: 10.1073/pnas.0504614102. View

18.

Grespi F, Melino G . P73 and age-related diseases: is there any link with Parkinson Disease?. Aging (Albany NY). 2012; 4(12):923-31. PMC: 3615159. DOI: 10.18632/aging.100515. View

19.

Chang J, Chiang M, Lin S, Lee M, He H, Chou P . TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis. 2012; 3:e302. PMC: 3358014. DOI: 10.1038/cddis.2012.36. View

20.

Shandilya J, Wang Y, Roberts S . TFIIB dephosphorylation links transcription inhibition with the p53-dependent DNA damage response. Proc Natl Acad Sci U S A. 2012; 109(46):18797-802. PMC: 3503221. DOI: 10.1073/pnas.1207483109. View